At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Erchonia HLS Laser +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled Randomized Evaluation of the Effect of the Erchonia® HLS Laser Device on Children With Autistic Disorder Clinical Study Protocol 2
In Brief
A clinical study evaluating Erchonia HLS Laser and Placebo Laser for Autistic Disorder. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to twelve (12) years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutistic Disorder
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedMay 2021
Primary CompletionFeb 2022
Study CompletionMar 2022
TodayJul 2026
First PostedMay 20, 2021
Enrollment StartNov 11, 2020
Primary CompletionFeb 17, 2022
Study CompletionMar 17, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.1 years ago
Interventions
Erchonia HLS Laserdevice
The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
Placebo Laserdevice
The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.